Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387700 | 0.94 | GABRA1 (0.46) | GABRA1GABRB1GABRB2FABP3FABP4 | |
| SCHEMBL10204235 | 0.84 | GABRA1 (0.39) | GABRA1GABRB1GABRB2FABP3FABP4 | |
| SCHEMBL338867 | 0.83 | GABRA1 (0.46) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL9967735 | 0.82 | GABRA1 (0.38) | GABRA1GABRB1GABRB2FABP3FABP4 | |
| SCHEMBL20483093 | 0.82 | GABRA1 (0.48) | GABRA1GABRB1GABRB2FABP3FABP4 | |
| SCHEMBL16959242 | 0.82 | GABRA1 (0.38) | GABRA1GABRB1GABRB2FABP3FABP4 | |
| SCHEMBL12263051 | 0.82 | GABRA1 (0.38) | GABRA1GABRB1GABRB2FABP3FABP4 | |
| SCHEMBL19304424 | 0.82 | GABRA1 (0.38) | GABRA1GABRB1GABRB2FABP3FABP4 | |
| SCHEMBL29927907 | 0.82 | GABRA1 (0.38) | GABRA1GABRB1GABRB2FABP3FABP4 | |
| SCHEMBL17032599 | 0.82 | GABRA1 (0.38) | GABRA1GABRB1GABRB2FABP3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638580-A | Compound, hole transport material and organic electroluminescent device | 烟台显华科技集团股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-114989200-B | Boron-containing nitrogen compounds and their use in organic electronic devices | 广州追光科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240114772-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | SFC CO., LTD. (KP) | 2024-04-04 | — | — | US | disclosed |
| CN-116367573-A | Organic light emitting diode and organic light emitting display device having the same | 乐金显示有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230209987-A1 | ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DISPLAY DEVICE HAVING THE SAME | LG DISPLAY CO., LTD. (KR) | 2023-06-29 | — | — | US | disclosed |
| US-20230209987-A1 | ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DISPLAY DEVICE HAVING THE SAME | LG DISPLAY CO., LTD. (KR) | 2023-06-29 | — | — | US | disclosed |
| US-20230209987-A1 | ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DISPLAY DEVICE HAVING THE SAME | LG DISPLAY CO., LTD. (KR) | 2023-06-29 | — | — | US | disclosed |
| CN-115636755-A | Naphthyl substituted diarylamine compound and application thereof | 烟台显华科技集团股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-114989200-A | Boron-containing nitrogen compounds and their use in organic electronic devices | 广州追光科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-110177798-B | Catalyst and process for preparing same | 博里利斯股份公司 | 2022-08-30 | — | — | CN | disclosed |
| US-6506750-B1 | N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle. | SANOFI-SYNTHELABO (FR) | 2003-01-14 | — | — | US | disclosed |
| CN-1353698-A | Novel morpholine derivatives, method for production thereof and pharmaceutical preparations containing said derivatives | SANOFI SYNTHELABO (FR) | 2002-06-12 | — | — | CN | disclosed |
| US-6403638-B1 | COMPOUND FOR USE IN TREATING SKIN DISEASES AND DISORDERS, AND FOR TREATING HYPERVITAMINOSIS A SYNDROME | ALLERGAN SALES, INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| CN-1328538-A | 2, 4-pentadienoic acid derivatives having selective activity for Retinoid X (RXR) receptor | ALLERGAN SALES INC (US) | 2001-12-26 | — | — | CN | disclosed |
| WO-2001070662-A2 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN , INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1117628-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan Sales, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6147224-A | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN SALES, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000020370-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240114772-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | L1CAM, EPCAM, OR10J3 | GABRA1 4331/4885GABRB1 4401/4885GABRB2 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.